189 related articles for article (PubMed ID: 18008038)
1. Iron, hepatitis C virus, and hepatocellular carcinoma: iron reduction preaches the gospel for chronic hepatitis C.
Fujita N; Takei Y
J Gastroenterol; 2007 Nov; 42(11):923-6. PubMed ID: 18008038
[No Abstract] [Full Text] [Related]
2. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C.
Kato J; Miyanishi K; Kobune M; Nakamura T; Takada K; Takimoto R; Kawano Y; Takahashi S; Takahashi M; Sato Y; Takayama T; Niitsu Y
J Gastroenterol; 2007 Oct; 42(10):830-6. PubMed ID: 17940836
[TBL] [Abstract][Full Text] [Related]
3. [Alternative measures for patients with chronic hepatitis C unresponsive to interferon therapy].
Imazeki F
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):540-3. PubMed ID: 15359858
[No Abstract] [Full Text] [Related]
4. [Phlebotomy, dietary iron restriction therapy and bovine lactoferrin therapy for chronic hepatitis C].
Kaito M; Iwasa M; Adachi Y; Iwata K; Yamauchi K
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):534-9. PubMed ID: 15359857
[No Abstract] [Full Text] [Related]
5. The role of iron in the pathophysiology and treatment of chronic hepatitis C.
Price L; Kowdley KV
Can J Gastroenterol; 2009 Dec; 23(12):822-8. PubMed ID: 20011735
[TBL] [Abstract][Full Text] [Related]
6. Incidence of hepatocellular carcinoma reduced by phlebotomy treatment in patients with chronic hepatitis C.
Nirei K; Matsuoka S; Nakamura H; Matsumura H; Moriyama M
Intern Med; 2015; 54(2):107-17. PubMed ID: 25743000
[TBL] [Abstract][Full Text] [Related]
7. Normalization of elevated hepatic 8-hydroxy-2'-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet.
Kato J; Kobune M; Nakamura T; Kuroiwa G; Takada K; Takimoto R; Sato Y; Fujikawa K; Takahashi M; Takayama T; Ikeda T; Niitsu Y
Cancer Res; 2001 Dec; 61(24):8697-702. PubMed ID: 11751387
[TBL] [Abstract][Full Text] [Related]
8. Prevention of hepatocellular carcinoma.
Kew MC
Ann Hepatol; 2010; 9(2):120-32. PubMed ID: 20526004
[TBL] [Abstract][Full Text] [Related]
9. [Risk of hepatocellular carcinoma after hepatitis C virus cure with direct-acting antivirals: the next challenges].
Hamdane N; Baumert TF; Zeisel MB
Med Sci (Paris); 2018 May; 34(5):391-394. PubMed ID: 29900836
[No Abstract] [Full Text] [Related]
10. Hepatitis viruses and hepatocellular carcinoma.
Kew MC
Res Virol; 1998; 149(5):257-62. PubMed ID: 9879602
[No Abstract] [Full Text] [Related]
11. Additional effect of low iron diet on iron reduction therapy by phlebotomy for chronic hepatitis C.
Kimura F; Hayashi H; Yano M; Yoshioka K; Matsumura T; Fukuda T; Shigeto N; Yamahara S; Koushi F; Mishima Y; Yoshino T; Tanimoto M; Kimura I
Hepatogastroenterology; 2005; 52(62):563-6. PubMed ID: 15816478
[TBL] [Abstract][Full Text] [Related]
12. Viral hepatitis and hepatocellular carcinoma.
Marrero CR; Marrero JA
Arch Med Res; 2007 Aug; 38(6):612-20. PubMed ID: 17613352
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effect of phlebotomy on hepatitis C virus-associated musculoskeletal manifestations.
Hilzenrat N; Buskila D; Zilberman D; Sikuler E
Clin Rheumatol; 1998; 17(5):390-2. PubMed ID: 9805184
[TBL] [Abstract][Full Text] [Related]
14. Prevention of hepatitis C virus-related hepatocellular carcinoma.
Heathcote EJ
Gastroenterology; 2004 Nov; 127(5 Suppl 1):S294-302. PubMed ID: 15508097
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathogenesis of human hepatocellular carcinoma.
Kern MA; Breuhahn K; Schirmacher P
Adv Cancer Res; 2002; 86():67-112. PubMed ID: 12374281
[No Abstract] [Full Text] [Related]
16. Emerging therapies of hepatitis B and C.
Chen RY; Desmond PV; Locarnini SA
J Gastroenterol Hepatol; 2002 Dec; 17 Suppl():S471-81. PubMed ID: 12534781
[No Abstract] [Full Text] [Related]
17. [Occurrence of hepatocellular carcinoma in patients with chronic hepatitis C who continued to be HCV-RNA negative for up to 3 years by interferon].
Miyao N; Serizawa H; Kumagai N; Takaishi H; Watanabe N; Hamada Y; Tsuchimoto K; Takeuchi O; Toyoda H; Kuramochi S; Ishii H
Nihon Shokakibyo Gakkai Zasshi; 1999 May; 96(5):535-9. PubMed ID: 10368998
[No Abstract] [Full Text] [Related]
18. Long-term outcome after interferon therapy in patients with chronic hepatitis C.
Buti M; Esteban R
Ann Hepatol; 2007; 6(4):267-9. PubMed ID: 18007558
[No Abstract] [Full Text] [Related]
19. Iron and hepatitis C: what can we learn from thalassemia major?
Mahmoud A; Musallam KM; Taher AT
Liver Int; 2008 Jul; 28(6):892-3; author reply 893. PubMed ID: 18647144
[No Abstract] [Full Text] [Related]
20. A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C.
Fong TL; Han SH; Tsai NC; Morgan TR; Mizokami M; Qian D; Phan C; Goad K; Redeker AG
J Hepatol; 1998 Mar; 28(3):369-74. PubMed ID: 9551672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
